Pluristem Therapeutics, Inc. ( PSTI ), a bio-therapeutics company, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. PLURISTEM THERA (PSTI): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PSTI's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Pluristem Therapeutics could be a solid choice for investors.
Current Quarter Estimates for PSTI
Though there has been no upward or downward revision for Pluristem Therapeutics in the past 30 days, consensus estimate trend has been favorable for the company. Estimates have narrowed from a loss of 14 cents a share 30 days ago, to a loss of 13 cents today, a move of 7.1%.
Current Year Estimates for PSTI
Meanwhile, Pluristem Therapeutics's current year figures are also looking quite promising. Though there has been no upward or downward revision for the company in the past month, consensus estimate trend has seen a boost for this time frame. Estimates have narrowed from a loss of 61 cents a share 30 days ago, to a loss of 54 cents today, a move of 11.5%.
The stock has also started to move higher lately, adding 27.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>